Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 123 Published: November 30, 2021 Report Code: GMDGDHC3010TDB

Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain and plays an important role in inflammation.

The Non Receptor Tyrosine Protein Kinase TYK2 drugs in development market research report provides comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

What are the key therapy areas in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market?

The key therapy areas in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market are immunology, gastrointestinal, musculoskeletal disorders, dermatology, oncology, central nervous system, infectious disease, metabolic disorders, and respiratory.

Non Receptor Tyrosine Protein Kinase TYK2 Pipeline Products Market Analysis by Therapy Area

Non Receptor Tyrosine Protein Kinase TYK2 Pipeline Products Market Analysis by Therapy Area

For more therapy area insights, download a free report sample

What are the key indications in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market?

The key indications in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market are psoriasis, inflammatory bowel disease, systemic lupus erythematosus, ulcerative colitis, rheumatoid arthritis, Crohn’s disease (regional enteritis), plaque psoriasis (psoriasis vulgaris), atopic dermatitis (atopic eczema), autoimmune disorders, psoriatic arthritis, and others.

Non Receptor Tyrosine Protein Kinase TYK2 Pipeline Products Market Analysis by Indications

Non Receptor Tyrosine Protein Kinase TYK2 Pipeline Products Market Analysis by Indications

For more indication insights, download a free report sample

What are the key mechanisms of action in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market?

The key mechanism of action in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market is Non Receptor Tyrosine Protein Kinase TYK2 Inhibitor.

What are the key routes of administration in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market?

The key routes of administration in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market are oral, topical, ophthalmic, and intravitreal.

Non Receptor Tyrosine Protein Kinase TYK2 Pipeline Products Market Analysis by Routes of Administration

Non Receptor Tyrosine Protein Kinase TYK2 Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

What are the different molecule types in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market?

The molecule type in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market is small molecule.

Which are the major companies in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market?

Some of the major companies in the Non Receptor Tyrosine Protein Kinase TYK2 pipeline products market are AbbVie Inc, Alexion Pharmaceuticals Inc, Amgen Inc, Atomwise Inc, Bristol-Myers Squibb Co, Esker Therapeutics Inc, Galapagos NV, Haisco Pharmaceutical Group Co Ltd, InnoCare Pharma Ltd, and Merck & Co Inc

Non Receptor Tyrosine Protein Kinase TYK2 Pipeline Products Market Analysis by Companies

Non Receptor Tyrosine Protein Kinase TYK2 Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Scope

Key therapy area Immunology, Gastrointestinal, Musculoskeletal Disorders, Dermatology, Oncology, Central Nervous System, Infectious Disease, Metabolic Disorders, and Respiratory
Key indications Psoriasis, Inflammatory Bowel Disease, Systemic Lupus Erythematosus, Ulcerative Colitis, Rheumatoid Arthritis, Crohn’s Disease (Regional Enteritis), Plaque Psoriasis (Psoriasis Vulgaris), Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Psoriatic Arthritis, and Others
Key mechanism of action Non Receptor Tyrosine Protein Kinase TYK2 Inhibitor
Key routes of administration Oral, Topical, Ophthalmic, and Intravitreal
Molecule type Small Molecule
Major companies AbbVie Inc, Alexion Pharmaceuticals Inc, Amgen Inc, Atomwise Inc, Bristol-Myers Squibb Co, Esker Therapeutics Inc, Galapagos NV, Haisco Pharmaceutical Group Co Ltd, InnoCare Pharma Ltd, and Merck & Co Inc

Scope

  • The report provides a snapshot of the global therapeutic landscape of Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)
  • The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews the latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage
  • Identify and understand the targeted therapy areas and indications for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Players

AbbVie Inc

Alexion Pharmaceuticals Inc

Amgen Inc

Atomwise Inc

Bristol-Myers Squibb Co

Esker Therapeutics Inc

Galapagos NV

Haisco Pharmaceutical Group Co Ltd

InnoCare Pharma Ltd

Merck & Co Inc

Neuron23 Inc

Nimbus Therapeutics LLC

Oncostellae SL

Pfizer Inc

Sareum Holdings Plc

Shenzhen Chipscreen Biosciences Co Ltd

Simcere Pharmaceutical Group Ltd

Technoderma Medicines Inc

Theravance Biopharma Inc

TLL Pharmaceutical LLC

Ventyx Biosciences Inc

Table of Contents

Table of Contents

Introduction

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) – Overview

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) – Therapeutics Development

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) – Therapeutics Assessment

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) – Companies Involved in Therapeutics Development

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) – Drug Profiles

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) – Dormant Products

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) – Discontinued Products

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indications, 2021

Number of Products under Development by Indications, 2021 (Contd..1)

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Companies, 2021 (Contd..3)

Products under Development by Companies, 2021 (Contd..4)

Products under Development by Companies, 2021 (Contd..5)

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by AbbVie Inc, 2021

Pipeline by Alexion Pharmaceuticals Inc, 2021

Pipeline by Amgen Inc, 2021

Pipeline by Atomwise Inc, 2021

Pipeline by Bristol-Myers Squibb Co, 2021

Pipeline by Esker Therapeutics Inc, 2021

Pipeline by Galapagos NV, 2021

Pipeline by Haisco Pharmaceutical Group Co Ltd, 2021

Pipeline by InnoCare Pharma Ltd, 2021

Pipeline by Merck & Co Inc, 2021

Pipeline by Neuron23 Inc, 2021

Pipeline by Nimbus Therapeutics LLC, 2021

Pipeline by Oncostellae SL, 2021

Pipeline by Pfizer Inc, 2021

Pipeline by Sareum Holdings Plc, 2021

Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2021

Pipeline by Simcere Pharmaceutical Group Ltd, 2021

Pipeline by Technoderma Medicines Inc, 2021

Pipeline by Theravance Biopharma Inc, 2021

Pipeline by TLL Pharmaceutical LLC, 2021

Pipeline by Ventyx Biosciences Inc, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Frequently Asked Questions

Enquire Before Buying
$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.